Avaliação de polimorfismo da enzima citocromo P450 em pacientes com síndrome antifosfolípide e seu impacto no controle da anticoagulação

Rodrigues, Carlos Ewerton Maia; Carvalho, Jozélio Freire de; Araujo, Roberto Paulo Correia de.
Rev. Ciênc. Méd. Biol. (Impr.) ; 19(3): 514-517, dez 5, 2020.
Artículo en Portugués | LILACS | ID: biblio-1358034

Documentos relacionados

  1. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various <i>CYP2C9</i> Genotypes under Different Cotreatments.
  2. Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients.
  3. Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents.
  4. Relationship of S/R warfarin ratio with CYP2C9 genotypes in Pakistani population.
  5. Safflower yellow for injection enhances anti-coagulation of warfarin in rats: implications in pharmacodynamics and pharmacokinetics.
  6. The Safety of Continued Oral Anticoagulation Therapy in Joint Injections and Aspirations: A Qualitative Review of the Current Evidence.
  7. Deciphering Genetic Variants of Warfarin Metabolism in Children With Ventricular Assist Devices.
  8. Individual Differences in Metabolic Clearance of S-Warfarin Efficiently Mediated by Polymorphic Marmoset Cytochrome P450 2C19 in Livers.
  9. [Effect of genetic variations on adjusting of warfarin dose].
  10. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.